Reported a net loss of $10.3 million for the three months ended March 31, 2026, compared to a $23.4 million loss in the same period of 2025. Operating expenses decreased to $11.2 million from $24.6 million in Q1 2025, primarily due to the discontinuation of the Alzheimer's disease program. Cash and cash equivalents stood at $86.6 million as of March 31, 2026. The company is currently under a full clinical hold by the FDA regarding its IND application for simufilam in TSC-related epilepsy. Management believes current working capital is sufficient to fund operations for at least the next 12 months.